Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.

Authors

Jeffrey A. Scott

Integra Connect PrecisionQ, West Palm Beach, FL

Jeffrey A. Scott , Harvey I. Katzen , Jochen K Lennerz , Melissa Lynne Johnson , Lucio N. Gordan , Robert H Dumanois , Luca Quagliata , Lauren Ritterhouse , Federico Cappuzzo , Anupama Vasudevan , Teena Sura , Sandy English , Brandon Wang , Prateesh Varughese , Rushir J. Choksi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9030)

DOI

10.1200/JCO.2023.41.16_suppl.9030

Abstract #

9030

Poster Bd #

Abstract Disclosures

FEATURED

Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.

Authors

Jeffrey A. Scott

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Evaluation of outcomes in patients (pts) with stage 4 non-small cell lung cancer (NSCLC 4) harboring actionable oncogenic drivers (AOD) when treated prior to report of mutation without tyrosine kinase inhibitors (TKI): An Integra Connect Database (ICD) retrospective observational study.

Poster

Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).

Poster

Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRAS and MET in non-small cell lung cancer.

Poster

Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).